

# Development of Broadly Neutralizing Antibodies in the IAVI Protocol C HIV Primary Infection Cohort



**DATE:** Thursday, March 14, 2019

**TIME:** 4:00p- 5:00p

**VENUE:** Pelton Auditorium

1100 Fairview Ave N, Seattle WA  
98109

**Featuring Elise Landais, PhD**

Senior Research Scientist

The Scripps Research Institute

**Live Webcast Available!**

For more  
information:



[cfar@uw.edu](mailto:cfar@uw.edu)  
[cfar.uw.edu/events](http://cfar.uw.edu/events)

*Dr. Elise Landais* earned her PhD in Immunology in 2005 from the University of Nantes, France, characterizing CD4+T cell responses against Epstein-Barr Virus and evaluating their potential for EBV-associated lymphoma immunotherapy. Dr Landais joined the IAVI NAC in 2011 to work with Dr. Pascal Poignard on the IAVI Protocol C primary infection cohort, leading studies on broadly neutralizing antibodies (bnAbs) development in the context of HIV evolution, in order to understand the molecular events leading to acquisition of neutralization breadth during natural infection and inform vaccine design. She joined Dr Devin Sok's group in 2018 to continue and extend this work beyond discovery and HIV as part of IAVI's broader mission.